These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37699957)

  • 21. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.
    van der Ende EL; Meeter LH; Poos JM; Panman JL; Jiskoot LC; Dopper EGP; Papma JM; de Jong FJ; Verberk IMW; Teunissen C; Rizopoulos D; Heller C; Convery RS; Moore KM; Bocchetta M; Neason M; Cash DM; Borroni B; Galimberti D; Sanchez-Valle R; Laforce R; Moreno F; Synofzik M; Graff C; Masellis M; Carmela Tartaglia M; Rowe JB; Vandenberghe R; Finger E; Tagliavini F; de Mendonça A; Santana I; Butler C; Ducharme S; Gerhard A; Danek A; Levin J; Otto M; Frisoni GB; Cappa S; Pijnenburg YAL; Rohrer JD; van Swieten JC;
    Lancet Neurol; 2019 Dec; 18(12):1103-1111. PubMed ID: 31701893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers.
    Murueta-Goyena A; Cipriani R; Carmona-Abellán M; Acera M; Ayo N; Del Pino R; Tijero B; Fernández-Valle T; Gabilondo I; Zallo F; Matute C; Sánchez-Pernaute R; Khurana V; Cavaliere F; Capetillo-Zarate E; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2022 Mar; 96():29-35. PubMed ID: 35149357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.
    Pagonabarraga J; Pérez-González R; Bejr-Kasem H; Marín-Lahoz J; Horta-Barba A; Martinez-Horta S; Aracil-Bolaños I; Sampedro F; Campolongo A; Rivas E; Puig-Davi A; Ruiz-Barrios I; Pérez-Pérez J; Pascual-Sedano B; Kulisevsky J
    Parkinsonism Relat Disord; 2022 Dec; 105():132-138. PubMed ID: 35752549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Neurofilament Light With the Development and Severity of Parkinson Disease.
    Halloway S; Desai P; Beck T; Aggarwal N; Agarwal P; Evans D; Rajan KB;
    Neurology; 2022 May; 98(22):e2185-e2193. PubMed ID: 35418452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
    Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
    Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
    Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
    Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
    Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
    J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson's disease dementia.
    Frigerio I; Laansma MA; Lin CP; Hermans EJM; Bouwman MMA; Bol JGJM; Galis-de Graaf Y; Hepp DH; Rozemuller AJM; Barkhof F; van de Berg WDJ; Jonkman LE
    Transl Neurodegener; 2023 Jan; 12(1):3. PubMed ID: 36658627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.
    Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Shenhar-Tsarfaty S; Mirelman A
    J Neurol; 2021 Apr; 268(4):1517-1525. PubMed ID: 33388928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated α-synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson's disease.
    Lin CW; Lai TT; Chen SJ; Lin CH
    Geroscience; 2022 Jun; 44(3):1551-1562. PubMed ID: 35484471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study.
    Shim Y
    Dement Neurocogn Disord; 2022 Apr; 21(2):59-70. PubMed ID: 35585907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood Neurofilament Light Chain in Different Types of Dementia.
    Gu L; Shu H; Wang Y; Wang P
    Curr Alzheimer Res; 2023; 20(3):149-160. PubMed ID: 37264656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between serum neurofilament light chain levels and sleep disorders in patients with Parkinson's disease.
    Li Y; Li F; Liu X; Zu J; Zhang W; Zhou S; Zhu J; Zhang T; Cui G; Xu C
    Neurosci Lett; 2023 Aug; 812():137394. PubMed ID: 37437874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson's disease patients.
    Dong L; Chang Q; Ma J; Liu C; Guo D; Li X; Yang D; Fan Y; Liang K; Li D; Gu Q
    Neurosci Lett; 2023 May; 804():137219. PubMed ID: 37023526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.